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R
(Is Reclassification of
Intermediate-Risk Subjects
by Coronary Artery Calcium
Scoring Clinically Useful?
In a population-based cohort of 4,129 subjects without overt
coronary artery disease at baseline, Erbel et al. (1) demonstrated
that coronary artery calcium (CAC) scoring provides a significant
improvement in discrimination and a high level of correct reclas-
sification when applied to persons initially identified by the
Framingham criteria as having an intermediate risk for coronary
events. The investigators concluded that “limiting CAC scoring to
intermediate-risk subjects can contribute to reducing the number
of coronary events in the general population.” Because prediction
does not necessarily lead to prevention, we should scrutinize the
level of scientific evidence on the ability of CAC scoring to
improve health outcomes.
To reduce disease-specific morbidity or mortality, the process of
reclassification should be able to select subjects to more intensive
treatment of modifiable risk factors. According to results derived
from the investigators’ Table 3 (1), 77% of correct reclassification
n subjects with 10% to 20% risk was confined to down-
lassification of those without events. Obviously, this type of
eclassification does not induce physicians to enhance preventive
trategies. In contrast, there is no scientific evidence that it is safe
o downgrade preventive care on the basis of a low CAC score.
hus, 77% of correct reclassification obtained by CAC scoring
hould have no impact on clinical management and outcomes.
And what about up-classification of those with events, which took
lace in the remaining 23% of correct reclassification (1)? Should it
modify preventive strategies? Regarding statin therapy, a reduction in
coronary events has been recently demonstrated by aggressive lipid
lowering in intermediate-risk subjects with normal low-density lipo-
protein cholesterol levels (2). Thus, it is unlikely that CAC scoring
will modify the recommendations for statin therapy in this population.
Second, the indication for initiating drug therapy in patients with
hypertension and target blood pressure values should not differ
between intermediate-risk and high-risk subjects (3). Finally, should
spirin be used in subjects reclassified to high risk? The magnitude of
bsolute risk reduction of cardiovascular events by aspirin in primary
revention is small, and the risk/benefit ratio does not justify its use in
ost subjects (4). Recently, the long-term beneficial effect of aspirin
n patients with diabetes has been questioned in several randomized
linical trials (5), suggesting that aspirin is justified only for very
igh-risk patients, mostly in the secondary prevention setting. In
ddition, aspirin did not prove beneficial in a clinical trial focused on
symptomatic subjects with subclinical atherosclerosis assessed by
nkle-brachial index (6). Finally, lifestyle measures, such as smoking
essation, weight control, and exercise, are universally recommended,
egardless of risk profile. wTherefore, the utility of reclassifying intermediate-risk subjects
may be a questionable paradigm, and before implementing such a
strategy, the efficacy of using CAC scoring should be tested by
appropriate clinical trials comparing the incidence of cardiovascu-
lar events between subjects randomized to CAC scoring and those
randomized to no CAC scoring.
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Reply
We thank Drs. Correia and Rassi for their interest in our study (1)
and for addressing important issues for clinical decision making
using coronary artery calcium (CAC) scoring. Current strategies of
risk prediction are based predominantly on traditional risk factors
and have been proven very successful in populations. However, on
an individual level, misclassification is common. In 2010, 3 groups
independently published studies about the value of CAC scoring
for discrimination in the general population when added to
traditional risk factors: in MESA (Multi-Ethnic Study of Athero-
sclerosis), CAC scoring improved the discrimination of coronary
events including revascularization, with net reclassification im-
provement (NRI) of 25% (2); in the HNR (Heinz Nixdorf Recall)
study, CAC scoring improved the discrimination of hard coronary
events (i.e., cardiac death and myocardial infarction; NRI  30%)
1); and in the Rotterdam Study, hard coronary event prediction
as significantly improved in an elderly cohort (NRI  14%) (3).
